

## Special Issue

# Tumor Heterogeneity and Resistance to Cancer Therapies

### Message from the Guest Editor

The sequences of cancer genomes and the development of oncogene-specific inhibitors have transformed the clinical treatment of cancer patients into what is commonly known as precision or personalized medicine.

However, it's widely known that each tumor contains a "private" collection of molecular alterations, few of which are shared between patients with the same histopathological subtype. The critical role of molecular heterogeneity and clonal evolution in the clinical outcomes of cancer patients leads to many clinical and scientific needs:

- Clinical trials, novel technologies and biomarker studies providing accurate molecular maps of individual tumors and longitudinal analyses of tumor evolution during therapeutic treatment.
- Preclinical models of patients' specific disease allowing the rapid identification of the most effective personalized therapy.
- The identification of common (trunk) cell vulnerabilities suitable for therapeutic targeting.
- Innovative therapeutic strategies able to overcome the challenges posed by tumor heterogeneity and to prevent clonal evolution.

---

### Guest Editor

Dr. Mariangela Russo

1. Department of Oncology, University of Torino, Candiolo, Italy
2. Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy

---

### Deadline for manuscript submissions

closed (30 November 2022)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/78614](https://mdpi.com/si/78614)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).